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Abstract
Background. Ivermectin (IVM) reduces the lifespan of malaria-transmitting mosquitoes after feeding on humans treated with
IVM. If this effect is sufficiently long and strong, IVM could form part of a drug combination that not only treats malaria
patients but also reduces onward transmission. Limited data are available on the exact duration of the mosquitocidal effect of
IVM; daily mosquito feeding assays are required for this.
Materials and Methods. We determined mortality rates of Anopheles stephensi mosquitoes that took a blood meal on Swiss
mice, Wistar rats and Cynomolgus monkeys that received IVM orally at 200-400 µg/kg. Mosquito feeding assays were
performed on five consecutive days after IVM administration. Mosquito mortality was determined in the first 72 hours after
feeding.
Results. Mosquito mortality was 70-100% when mosquitoes fed on any of the animals 1-2 days after the last IVM administra-
tion. After this time-point the mosquitocidal effect was still evident in some animals but became more variable.
Conclusions. Our findings of a pronounced but short-lived mosquitocidal effect makes the timing of IVM administration
crucial to form a useful addition to anti-malarial drugs.
1 Introduction
The search for malaria transmission-blocking drugs has
so far focused on drugs that clear gametocytes, the sex-
ual stage of Plasmodium parasites that are responsible
for the transmission of malaria to mosquitoes. An alter-
native/supplementary approach to prevent malaria trans-
mission after treatment would be a strategy that kills
mosquitoes before they become infectious after feeding on
a gametocytaemic blood meal. Ivermectin (IVM) may fulfil
a role in such a strategy. IVM is a drug with broad-spectrum
activity against nematodes and ectoparasites, and is widely
used in mass treatment campaigns against onchocerciasis
[1]. It has recently received much attention because of the
reduced lifespan of malaria-transmitting mosquitoes after
feeding on humans and cattle treated with IVM [2-5]. This
makes IVM a potentially attractive component of malaria
control efforts, where it could be part of a drug combination
that not only treats malaria patients but also reduces onward
transmission of the disease. The duration of the mosquito-
cidal effect of IVM is key to its potential role as an adjunct
malaria therapy. Few data are available on the exact dura-
tion of this effect.
Fritz and colleagues showed previously that addition of
IVM to bovine blood that is directly fed to Anopheles gam-
biae s.s. and An. arabiensis mosquitoes reduces their
survivorship and fecundity [5], and that IVM is already
lethal to An. arabiensis at low concentrations (LC50 of 7.9
ppb)[6]. Work in rodents and cattle suggests a long-acting
effect of IVM on anophelines; affecting mosquito survival
rates as long as 10 days after feeding on an IVM-treated
animal [5,7]. Chaccour and colleagues directly fed An.
gambiae mosquitoes on healthy human volunteers 1 and 14
days post-IVM administration and observed an increased
mortality at only the first time-point [2]. In a study from
Papua New Guinea, blood-fed mosquitoes were collected
from the huts of people 1-3 days and 28 days after an IVM
mass treatment campaign. An. punctulatus or An. kolien-
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Table 1. Mosquito feeding experiments after ivermectin (IVM) treatment in different animals.
     Mortality on experiment day #,  % (n/N) 
 Animal species # of animals # of 
treatment 
days 
Daily dose 
(Pg/kg) 
 
1* 
 
2* 
 
3* 
 
4* 
 
5* 
 Swiss mouse 2 1 400 100 (17/17) 89.5 (17/19) 0.0 (0/7) 0.0 (0/11) 9.1 (1/11) 
 2 2 400 100 (17/17) 95.2 (20/21) 85.7 (18/21) 37.5 (6/16) 65.6 (21/32) 
 2 3 400 100 (22/22) 87.5 (21/24) 0.0 (0/6) 6.3 (1/16) 0.0 (0/16) 
 2 4 400 100 (20/20) 100 (24/24) 66.7 (18/27) 50.0 (11/22) 30.4 (7/23) 
 2 5 400 100 (25/25) 88.5 (23/26) 67.9 (19/28) 52.0 (13/25) 0.0 (0/27) 
 Wistar rat 1 1 400 100 (22/22) 100 (24/24) 65.4 (17/26) 44.1 (15/34) 29.4 (10/34) 
 1 2 400 92.9 (26/28) 85.0 (17/20) 96.2 (25/26) 42.9 (15/35) 16.7 (3/18) 
 1 3 400 85.0 (17/20) 100 (29/29) 72.4 (21/29) 53.8 (21/39) 45.7 (16/35) 
 1 4 400 84.6 (22/26) 91.7 (22/24) 66.7 (12/18) 13.3 (4/30) 18.5 (5/27) 
 1 5 400 100 (16/16) 100 (19/19) 77.8 (14/18) 31.4 (11/35) 35.7 (10/28) 
 Cynomolgus 
monkey 
1 1 200 100 (10/10) 76.9 (10/13) 37.5 (3/8) 14.3 (1/7) 12.5 (1/8) 
 1 1 200 100** 91** 86** 0** 0** 
 1 1 400 100** 92** 45** 72** 8** 
 * Determined in the first 72 hours after feeding; ** Only the proportion of dead mosquitoes was recorded for these experiments 
   
sis caught 1-3 days post-treatment showed 70% mortality
within 24 hours after capture compared to 2% caught 28
days post-treatment [8]. A study from Senegal similarly de-
termined survival in blood-fed An. gambiae s.s. mosquitoes
sampled from houses after IVM mass treatment campaigns
and found that survival rates were lower for mosquitoes that
were caught 1-6 days post treatment; the effect for the indi-
vidual days was not reported [4]. A study where An. farauti
mosquitoes were allowed to feed on the skin of a single In-
donesian volunteer 0, 7, 10, 14, 26 and 44 days after admin-
istration of 250 µg/kg IVM suggested that the mosquitoci-
dal effect may last for 14 days [3].
In short, precise estimates of the duration of the
mosquitocidal effect of IVM are unavailable and studies
have been hampered by logistical and ethical challenges
in performing frequently repeated mosquito feeding exper-
iments. We aimed to support the discussion on the best
strategy of IVM deployment by analysing previously con-
ducted and unpublished experiments on the mortality rate of
An. stephensi mosquitoes after feeding on different animals
treated with IVM at doses within the range that is recom-
mended for use in humans (200-400 µg/kg).
2 Materials and Methods
Experiments were performed at the Radboud University Ni-
jmegen Medical Centre animal facility in the period May
1986-October 1987, where the test animals and mosquitoes
were housed according to local and national guidelines.
Permission to conduct the experiments in this study was
given under approval number DGVGZ/VVP-83262. Swiss
mice (Mus musculus; n=10) weighing ∼25g each were
given forage containing 2mg/kg IVM. Oral take-up of 5g
of forage per day resulted in a total take-up of 10 µg IVM
per day per mouse, or a daily dose of 400 µg/kg IVM. Four
to five days old An. stephensi mosquitoes were allowed to
feed directly on the skin of all animals exactly 1, 2, 3, 4
and 5 days after IVM treatment. After each feeding experi-
ment fully engorged mosquitoes were selected. The median
number of fully engorged mosquitoes per mouse per feed-
ing day was 10 (interquartile range 10-13.25, total number
of mosquitoes=503). Mosquito mortality for each of the
five mosquito feeding days was compared with 15 mosquito
feeding experiments on untreated Swiss mice; an entirely
separate group of animals. Mice were given IVM treatment
for 1-5 days prior to the first feeding experiment. The to-
tal dose of IVM therefore differed between animals. How-
ever, we observed no effect of longer treatment on mosquito
mortality after the last dose of IVM (Table 1; p=0.87) and
animals were therefore combined and analysed as a group.
Wistar rats (Rattus norvegicus, n=5) weighing ∼120g
each were given Ivomec R© solution orally. Ivomec R© so-
lution containing 10 µg/ml IVM was diluted to 100 µg/ml
IVM using distilled water, and administered orally by sy-
ringe to reach a daily dose of 400 µg/kg IVM. Mosquito
feeding assays were performed as above. The median
number of fully engorged mosquitoes per rat per feeding
day was 26 (IQR 20-30, total number of mosquitoes=673).
Mosquito mortality for each of the five feeding days was
compared with 15 mosquito feeding experiments on a com-
pletely separate group of untreated Wistar rats. While IVM
was given 1-5 days prior to mosquito feeding, we observed
no effect of longer treatment on mosquito mortality after
the last dose of IVM (p=0.83) and animals were therefore
combined and analysed as a group.
Cynomolgus monkeys (Macaca fascicularis; n=3) were
given an orange containing Ivomec R© solution at a sin-
gle dose of 200 (n=2) or 400 µg/kg bodyweight (n=1).
Mosquito feeding assays were performed as above. The me-
dian number of fully engorged mosquitoes per monkey per
feeding day was 14 (IQR 10.5-16.5) and was not recorded
for all experiments. For some experiments only the pro-
MalariaWorld Journal, www.malariaworld.org 2 October 2012, Vol. 3, No. 10
Bastiaens et al. MWJ 2012, 3:10
portion of surviving mosquitoes was recorded; this did not
affect the statistical analysis where we used a single esti-
mate per mosquito feeding experiment (see below) but lim-
ited the information that could be given for individual ex-
periments on Cynomolgus monkeys (Table 1). Mosquito
mortality for each of the five feeding days was compared
with 21 mosquito feeding experiments on a separate group
of untreated Cynomolgus monkeys.
For each of the five time-points after IVM, the proportion
of mosquitoes that died within 72 hours after their blood
meal was compared with control experiments using STATA
version 12.0 (StataCorp LP, Texas, US). Because the num-
ber of animals was deemed too small to reliably estimate
clustering of individual mosquito observations that fed on
the same animal, we chose the most conservative analytical
approach: each feeding experiment contributed one obser-
vation of the proportion of mosquitoes that died within 72
hours after this feeding experiment. This continuous vari-
able was compared between test and control experiments
using a non-parametric Wilcoxon rank-sum test; a Bonfer-
roni correction was used to counteract the problem of mul-
tiple comparisons.
3 Results
In mice, the proportion of mosquitoes that died within 72
hours after their bloodmeal was strongly elevated when
feeding one or two days after IVM (Table 1; Figure 1a).
On these days 70-100% of mosquitoes died within 72 hours
after feeding on any of the IVM-treated mice compared to
0-10% in control mice (p<0.0001 for both days). Beyond
day two, higher mosquito mortality was still observed in
some animals but we no longer found evidence for a statis-
tically significantly elevated mosquito mortality compared
to control mice.
For rats, mosquito mortality was also most pronounced
for mosquitoes feeding one or two days after IVM: 85-
100% of all mosquitoes died within 72 hours after feed-
ing on any of the IVM-treated rats compared to 2-28% in
control rats (Table 1; Figure 1b; p=0.001 for day 1 and
p=0.0009 for day 2). Mosquito mortality decreased after
this time-point but remained significantly elevated up to day
4 after IVM-treatment (p=0.008).
Similar as in rats and mice, mosquito mortality in exper-
iments with Cynomolgus monkeys was highest when feed-
ing one or two days after IVM (Table 1; Figure 1c; 77-100%
mosquito mortality within 72 hours after feeding, p=0.002
for both days). On the third day after treatment, mosquito
mortality was more variable (38-86%) although still signif-
icantly higher than the control experiments (p=0.002).
A. Swiss mice 
B. Wistar rats 
C. Cynomolgus 
monkeys 
Post treatment interval (days) 
Figure 1. Mosquito mortality within 72 hours after feed-
ing on different animals treated with ivermectin (IVM).
Mosquito feeding experiments were conducted on five con-
secutive days following IVM treatment and mosquito mor-
tality was calculated for the first 72 hours. Plotted on the
X-axes is the day since the last IVM dose, plotted on the Y-
axes is the proportion of all fully fed mosquitoes that died
within 72 hours after their blood meal. Swiss mice (n=10)
and Wistar rats (n=5) received IVM 400 µg/kg for 1-5 days
(A and B). Cynomolgus monkeys (n=3) received a single
dose of IVM at 200 (n=2) or 400 µg/kg (n=1) (C). Dots in-
dicate the median mosquito mortality and error bars indi-
cate the interquartile range; for IVM-treated monkeys this
interquartile range equals the total range because only 3
monkeys received IVM. Lines are drawn between the esti-
mates of the median and do not represent fitted or smoothed
curves. * = statistically significant after adjusting p-values
for multiple comparisons.
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4 Discussion
We observed a pronounced effect of IVM on mosquito mor-
tality rates in all animal models. The strong but short-lived
mosquitocidal effect of IVM that we observed supports sev-
eral previous observations [2,4,8] with more detailed daily
assessments and a larger number of mosquito observations.
A strength of our study is that we have performed daily
mosquito feeding experiments in three animal species and
thereby are able to add an estimate of mortality on differ-
ent days post IVM to the available literature. Since the
mosquitocidal effect of IVM was previously shown to be
highly dependent on the concentration of IVM in plasma
[9], we interpret our finding that the mosquitocidal effect
becomes more variable after two days, as an indication for
inter-individual variation in IVM metabolism. Since we did
not determine IVM plasma concentrations in our study an-
imals, we were unable to address this further. This is a
shortcoming of the current study. We found no evidence
in literature that the plasma disposition of IVM differs be-
tween our animal models and humans. Since our findings
are consistent between the different animals, we consider
it plausible that also in humans the mosquitocidal effect of
IVM is limited to the first few days after treatment.
Our findings have implications for the next steps in eval-
uating IVM as a tool for use in malaria control. The strong
but short-lived mosquitocidal effect makes IVM less at-
tractive as a stand-alone drug for mass drug administra-
tion (MDA) campaigns that aim to reduce malaria trans-
mission. IVM may, however, be a potent addition to anti-
malarial drugs in MDA campaigns or to prevent transmis-
sion shortly after treatment of symptomatic malaria cases.
Current therapy for malaria patients is based on treatment
with artemisinin-combination therapy (ACT). Whilst ACTs
are highly effective against asexual parasite stages and im-
mature gametocytes, mature gametocytes persist for sev-
eral weeks after treatment [10]. As a result, there is a
pronounced but incomplete reduction of malaria transmis-
sion in the first 7-14 days after treatment [11-13]. Pri-
maquine (PQ) is the only currently available drug that can
play a role in reducing the infectious period after ACT
by actively clearing mature gametocytes. Addition of PQ
to ACT reduces the duration of gametocyte carriage four-
fold compared to ACTs alone [14]. However, a single
dose of PQ at the currently recommended concentration
(0.75 mg/kg) is associated with haemolysis in glucose-
6-phosphate-dehydrogenase (G6PD) deficient individuals
[15,16]. This sub-optimal safety profile hinders wide-scale
use of PQ in malaria control [17]. There are currently
no safe alternatives to PQ available, although dose-finding
studies to determine a lower but efficacious dose of PQ are
ongoing and the gametocytocidal activity and safety profile
of the drug candidate methylene blue are promising [18].
Adding IVM to ACTs may be a promising strategy to
further reduce post-treatment malaria transmission. For
this, the timing of IVM administration has to be optimised
to cover the period when an individual is most infectious,
which is plausibly the first week after initiation of treat-
ment with ACTs [11,19]. An attractive element of IVM as
a ’targeted vector control tool’ is that it acts against both
indoor and outdoor biting vectors and targets different ef-
fector molecules compared to indoor residual spraying with
insecticides and insecticide treated bednets [20,21]. An ad-
ditional benefit in terms of integrated disease management
would be the curative effect of IVM on intestinal strongy-
loidiasis, onchocerciasis and scabies [1]. Several important
safety and tolerability data of an ACT-IVM drug combina-
tion are needed to confirm its potential, as well as pharma-
cokinetic data to ensure there are no drug interactions that
may reduce the efficacy of the ACT or partner drug compo-
nent.
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